Since Medicare began covering obesity drugs in July, 700,000 new seniors have started GLP-1 treatments, with 70% using Eli Lilly's medicines. The coverage, part of a temporary "Bridge" program, allows eligible seniors to access weight loss drugs for a $50 monthly co-pay. Eli Lilly's injection Zepbound leads in usage, especially for patients with higher body weight and complications, while its oral pill Foundayo is preferred by those seeking convenience and moderate weight loss. The rollout has been smooth, with effective coordination by Medicare and drug companies, expanding access to these treatments for millions of seniors.
Eli Lilly's stock price on Pluang is USD 1,168.72 as of September 22, 2026, showing a 1.43% increase in one day. The company holds a market cap of $1.03 trillion, indicating its significant presence in the health sector. Despite the recent surge in seniors starting GLP-1 treatments, Pluang order activity shows more selling at 66% compared to 34% buying as of the same date and time.
Eli Lilly reported a remarkable 48% revenue growth driven by strong sales of Mounjaro and Zepbound, yet its stock price remains nearly flat this year. Despite recent stock volatility due to price cuts, acquisition charges, and competition concerns, a...
Novo Nordisk's shares fell over 7% after the company announced long-term targets that failed to reassure investors about competition in the weight-loss drug market. The Danish drugmaker plans to launch multiple blockbuster drugs by 2030 and aims for ...
Nvidia and Eli Lilly both exceeded earnings expectations, but Nvidia's AI-driven data center growth offers a stronger long-term investment opportunity. Nvidia posted $96.22 billion in revenue, driven by AI infrastructure demand and supply constraints...
Novo Nordisk's stock fell 7% following its capital markets day where it outlined a growth plan that aligns with industry peers rather than exceeding them, signaling slower future growth. The company highlighted the upcoming loss of U.S. patent exclus...
Eli Lilly will present mid-stage trial results for eloraTZP, a two-drug obesity treatment, on September 30. The data will show if the combo offers significantly better weight loss and tolerability than tirzepatide alone, crucial for sustaining the co...
